These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 15808577)

  • 1. Prograf produces a molecular environment favoring antifibrosis, an effect reversed by the addition of rapamune.
    Brook NR; Waller JR; Bicknell GR; Nicholson ML
    Transplant Proc; 2005; 37(1):148-9. PubMed ID: 15808577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel antifibrotic agent pirfenidone attenuates the profibrotic environment generated by calcineurin inhibitors in the rat salt-depletion model.
    Brook NR; Waller JR; Bicknell GR; Nicholson ML
    Transplant Proc; 2005; 37(1):130-3. PubMed ID: 15808571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine and rapamycin act in a synergistic and dose-dependent manner in a model of immunosuppressant-induced kidney damage.
    Brook NR; Waller JR; Bicknell GR; Nicholson ML
    Transplant Proc; 2005 Mar; 37(2):837-8. PubMed ID: 15848549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
    Lloberas N; Torras J; Alperovich G; Cruzado JM; Giménez-Bonafé P; Herrero-Fresneda I; Franquesa Ml; Rama I; Grinyó JM
    Nephrol Dial Transplant; 2008 Oct; 23(10):3111-9. PubMed ID: 18469305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of modern immunosuppressive agents on the development of intimal hyperplasia.
    Waller JR; Brook NR; Bicknell GR; Nicholson ML
    Transpl Int; 2004 Jan; 17(1):9-14. PubMed ID: 14551676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of sirolimus on calcineurin inhibitor-induced nephrotoxicity using renal expression of KLOTHO, an antiaging gene.
    Han DH; Piao SG; Song JH; Ghee JY; Hwang HS; Choi BS; Kim J; Yang CW
    Transplantation; 2010 Jul; 90(2):135-41. PubMed ID: 20562737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity.
    Brook NR; Waller JR; Bicknell GR; Nicholson ML
    J Surg Res; 2005 May; 125(2):137-43. PubMed ID: 15854665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the combination of rapamycin with tacrolimus or cyclosporin on experimental intimal hyperplasia.
    Waller JR; Murphy GJ; Bicknell GR; Toomey D; Nicholson ML
    Br J Surg; 2002 Nov; 89(11):1390-5. PubMed ID: 12390379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis.
    Gao XM; Wong G; Wang B; Kiriazis H; Moore XL; Su YD; Dart A; Du XJ
    J Hypertens; 2006 Aug; 24(8):1663-70. PubMed ID: 16877971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.
    Vogelbacher R; Wittmann S; Braun A; Daniel C; Hugo C
    Transplantation; 2007 Dec; 84(11):1492-9. PubMed ID: 18091526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin.
    Hoogduijn MJ; Crop MJ; Korevaar SS; Peeters AM; Eijken M; Maat LP; Balk AH; Weimar W; Baan CC
    Transplantation; 2008 Nov; 86(9):1283-91. PubMed ID: 19005411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy.
    Han SY; Jee YH; Han KH; Kang YS; Kim HK; Han JY; Kim YS; Cha DR
    Nephrol Dial Transplant; 2006 Sep; 21(9):2406-16. PubMed ID: 16728425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients.
    Balfour IC; Srun SW; Wood EG; Belsha CW; Marshall DL; Ferdman BR
    J Heart Lung Transplant; 2006 May; 25(5):518-22. PubMed ID: 16678029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified synthetic siRNA targeting tissue inhibitor of metalloproteinase-2 inhibits hepatic fibrogenesis in rats.
    Hu YB; Li DG; Lu HM
    J Gene Med; 2007 Mar; 9(3):217-29. PubMed ID: 17351970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of rapamycin in the progression of renal fibrosis.
    Damião MJ; Bertocchi AP; Monteiro RM; Gonçalves GM; Cenedeze MA; Feitoza CQ; Marques GD; Giannocco G; Mazzali M; Teixeira VP; Dos Reis MA; Pacheco-Silva A; Câmara NO
    Transplant Proc; 2007 Mar; 39(2):457-9. PubMed ID: 17362758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin and cyclosporine have different effects on expression of Ang-1 and Ang-2 and Tie2 in rat renal allograft with chronic allograft nephropathy.
    Ma X; Lu YP; Yang L; Song J; Luo GH; Shi YJ; Li YP
    Transplant Proc; 2008 Oct; 40(8):2804-7. PubMed ID: 18929866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.
    Bonegio RG; Fuhro R; Wang Z; Valeri CR; Andry C; Salant DJ; Lieberthal W
    J Am Soc Nephrol; 2005 Jul; 16(7):2063-72. PubMed ID: 15917339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease.
    Berthier CC; Wahl PR; Le Hir M; Marti HP; Wagner U; Rehrauer H; Wüthrich RP; Serra AL
    Nephrol Dial Transplant; 2008 Mar; 23(3):880-9. PubMed ID: 18042615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis.
    Neef M; Ledermann M; Saegesser H; Schneider V; Reichen J
    J Hepatol; 2006 Dec; 45(6):786-96. PubMed ID: 17050028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.